Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

Background Immune checkpoint inhibitors (ICIs) have been a major advance in cancer management. However, we still lack prospective real-world data regarding their usage in people with HIV infection (PWH).Methods The ANRS CO24 OncoVIHAC study (NCT03354936) is an ongoing prospective observational cohor...

Full description

Bibliographic Details
Main Authors: Olivier Lambotte, Pierre Delobel, Jean-Philippe Spano, Kevin Bihan, Dominique Costagliola, Christine Katlama, Anne-Geneviève Marcelin, Laurent Greillier, Baptiste Abbar, Armelle Lavole, Séverine Gibowski, Cathia Soulié, Lambert Assoumou, Raghiatou Baldé, Thierry Allegre, Alain Makinson, Olivia Zaegel-Faucher, Marianne Veyri, Mathilde Bertheau, Michèle Algarte Genin, Marine Baron
Format: Article
Language:English
Published: BMJ Publishing Group 2024-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/8/e009728.full

Internet

https://jitc.bmj.com/content/12/8/e009728.full

Similar Items